SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are newly developed agents for the treatment of T2DM, which increase urinary excretion of glucose via SGLT2 inhibition in the kidney and thereby prevent hyperglycemic episodes in diabetic animals and individuals [15].